As the population ages, the prevalence of degenerative spinal conditions is estimated to increase. With soaring healthcare costs, we must be vigilant in our accountability for proper resource allocation to ensure universal access. Significant recent increases in lumbar fusion rates have been observed in the US. Less is known regarding the Canadian experience. Our objective was to evaluate recent trends in lumbar fusion and determine how surgeon factors influence reoperation for spinal stenosis (SS) surgery. Longitudinal follow-up study of lumbar surgical procedures for SS using administrative databases. Data was gathered on patient-hospital encounters from April 1, 1995 to December 31, 2001. We analyzed trends in spinal fusion. Index procedures (decompressions or fusions) and surgeon variables, such as specialty (orthopaedics, neurosurgery) and volume (above or below thirty cases/year), were selected as predictors of patient reoperation for SS. Adjustments were made for age, gender, and comorbidity. Reoperation rates were evaluated at six weeks, one and two years and until maximal follow-up. 6128 patients were identified (4200 decompressions and 1928 fusions). Proportionally more fusions were performed over the study period when compared to decompressions (1:2.6 in 1995 versus 1:1.5 in 2001). Orthopaedic specialty and higher surgical volume were associated with increased proportion of fusions (p<
0.0001). Reoperation rate was higher for decompressions at two years (OR 1.4) but not at long-term follow-up to ten years. Surgeon specialty had no impact on reoperation rates. Lower surgical volume demonstrated a higher reoperation rate after adjusting for specialty (Hazard Ratio 1.28). Rates of lumbar spinal fusion have been increasing in Ontario, but at a lesser rate compared with the US. There is wide variation in surgical procedures between surgeon specialty and volume. Surgeon specialty had little impact on reoperation rates. Better long-term survival was observed in spinal surgeons with volumes over thirty cases per year after adjusting for surgeon specialty. Due to increasing rates of spinal fusion, the benefit of improved long-term survival in SS surgery with higher volume surgeons requires more detailed analysis before policy recommendations can be made.
Fat embolism syndrome (FES) is a potentially lethal condition commonly seen in poly-traumatised patients, particularly those with multiple long-bone fractures. Treatment has centered around supportive care and early fracture fixation. Several clinical small trials have suggested corticosteroids benefit patients with FES but its use remains controversial. Our objective was to determine the effect of corticosteroids in preventing FES in patients with multiple long-bone fractures. We conducted a meta-analysis of randomised trials, searching computerised databases for published studies from 1966–2006. Additionally, we performed hand searches of major orthopaedic journals, meeting proceedings, and texts. Our primary outcome was the rate of FES. Secondary outcomes included presence of hypoxia, petechiae, mortality, infection, and delayed union. Of the one hundred and four studies identified, nine were potentially eligible, and only seven met all our eligibility criteria. From our pooled analysis of three hundred and eighty-nine patients, we found that corticosteroids reduced the risk of FES by 78% (95%CI: 43–92%, heterogeneity p-value=0.62, I2=10%) and that only eight patients needed to be treated (NNT=7.5) to prevent one case of FES (95%CI: five to thirteen patients). We did not find any significant differences in the rates of mortality, infection, or delayed union. The current evidence suggests that the use of corticosteroids is beneficial in the prevention of fat embolism syndrome in patients with multiple long-bone fractures. The use of corticosteroids does not appear to significantly increase the risk of complications although a confirmatory large randomised trial is needed.